This single paragraph provides significant insight into internal priorities. It confirms that, as of 2025, Health officials were actively developing options to revise statutory price-reduction mechanisms to align them with changes to the NMFG. The nature of these changes, however, remains protected via redactions. The justifications for the redactions provide useful insights.
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News

